2 results
Approved WMOCompleted
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
Approved WMOCompleted
Primary: To explore the effect of the H1-antagonist hydroxyzine 50 mg on motor response, attention and impulsivity, using a test battery and task manipulations. Secondary: To explore the effect of the H1-antagonist hydroxyzine 50 mg on…